# Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

> **NCT00428909** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Chronic Myeloid Leukemia (CML)

## Interventions

- **DRUG:** Imatinib/Acetaminophen

## Key facts

- **NCT ID:** NCT00428909
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428909, "Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00428909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*